Medpace Holdings Inc

MEDPNASDAQ · USD
610.54USD0.00 (-3.70%)
699

Medpace Holdings Inc (MEDP) Covered Calls

Medpace Holdings Inc trades in the Diagnostics & Research industry with an IV Rank of 60.71%, average versus the past year. MEDP's highest covered call setup is the $690.00 strike expiring Nov 20, 2026, sorted by theoretical annualized return. It's 6.67% out of the money with 2 days to expiration, a 6.71% return until expiration, and a 1,223.87% theoretical annualized return. Across the setups shown, annualized returns run from 194.07% to 1,223.87% at strikes between $650.00 and $880.00, with 2 to 58 days to expiration, as of Nov 18, 2026.

Read more

Running MEDP covered calls helps you generate income from Medpace Holdings Inc shares you already own, turning a long stock position into a yield producing asset. A covered call means holding the underlying stock and selling a call option against it, collecting premium in exchange for capping upside at the strike. Use our scanner to find the best MEDP covered calls in real time and filter for the strikes, expiries, and premiums that fit your strategy.

A covered call pairs limited risk with a clear income profile. If MEDP stays below the strike at expiration, you keep the premium and the shares. If it rises above, you deliver the stock at the strike and still pocket the premium. Selling MEDP covered calls works best when implied volatility is elevated, since richer premiums improve the risk reward. Key inputs include strike selection relative to delta, days to expiration, annualized return, and probability of assignment, all of which determine whether a given MEDP covered call is worth writing.

Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, and Asia. It offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. The company also provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services.

2026-11-202690.006.670.255.304338.006.711223.87-0.04+0.14285.05
2026-11-202680.005.120.257.503338.005.16941.74-0.04+0.20237.25
2026-11-202670.003.580.057.902318.003.58653.97-0.01+0.23177.85
2026-11-202660.002.031.757.801488.002.30419.81-0.27+0.31696.05
2026-11-202650.000.485.2013.00833.001.29235.01-0.80+0.46197.80
2026-12-1830770.0019.030.054.9012318.0019.04231.68-0.01+0.08124.85
2027-01-1558880.0036.040.054.9023318.0036.05226.85-0.01+0.0514.85
2026-12-1830760.0017.490.054.9011318.0017.50212.87-0.01+0.08134.85
2027-01-1558860.0032.950.054.9021318.0032.96207.39-0.01+0.0634.85
2026-12-1830750.0015.940.054.9010318.0015.95194.07-0.01+0.0944.85

As of Nov 18, 2026

Prices move. This one stays.Lock in 5 years at a special price and save $1,503. Ending soon.See the Black Friday deal →

Stock Statistics

  • IndustryDiagnostics & Research
  • SectorHealthcare
  • IV Rank60.71% Moderate
  • Market cap (M$)17,078
  • 52 weeks high-12.02%
  • 52 weeks low63.68%
  • Analyst recommendationHold
    2.94
  • Target price$674.92
    10.54% above the current stock price
  • Dividend—
  • Payout ratio0.00%
  • Earnings date2027-02-08
  • P/E33.85
  • Future P/E30.98
  • EPS (ttm)18.04
  • EPS growth next 5 years12.98%

As of Nov 20, 2026